
Location
Headquarters: Lakeland, Florida, United States, North America
Region: Florida
Country: US
Continent: North America
About
WellDyne is a healthcare company specializing in pharmacy benefit management (PBM) services. It focuses on improving medication adherence, reducing overall healthcare costs, and delivering transparent, evidence-based clinical programs for plan sponsors and pharmacies. The company emphasizes innovative member engagement through intuitive technology and redesigned PBM experiences to achieve better health outcomes. Based in the United States, WellDyne presents itself as a bold partner in transforming the PBM landscape and simplifying benefits management.
WellDyne is a pharmacy benefit manager (PBM) that provides healthcare solutions to plan sponsors and pharmacies. The company manages retail and mail-order pharmacy networks, specialty pharmacy services, and clinical programs to reduce costs and improve medication adherence. It serves the middle market with data-driven analytics and customizable modular solutions.
WellDyne
1990
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Late Stage
unknown
50m-100m
private
Leadership
Technology Stack
Products
WellDyne Clear: A transparent pharmacy benefit management model focusing on net cost to reduce overall drug spend and improve cost control for plan sponsors.
Modular Pharmacy Services: Disaggregated pharmacy services including mail order, central fill, specialty pharmacy, clinical programs, and technology platforms offered as configurable components.
Formulary Management: Multiple formulary options including closed, open, and hybrid formularies designed to align drug selection with client goals and contain costs.
WellView Member Portal and Mobile App: Digital tools providing members with real-time access to pharmacy benefits, prescription information, and ID card management.
Clinical Programs and Utilization Management: Evidence-based clinical programs including prior authorization, generic management, and quantity limits to ensure appropriate drug use and control costs.
Funding rounds
Acquired · (2016-08-01)
